Industry landscapes
The companies, capital and talent shaping healthtech in the Netherlands. Find the leaders. Understand the segments. See where the activity is.
An industry ecosystem,
measured in context.
24 featured companies from the funding, hiring, revenue and team-size leaderboards.
Locked revenue figures are available in Radar; the eight company financial previews stay the same throughout this page. A dash means the figure is outside these featured lists. Revenue years vary by company; the figures are not a like-for-like revenue comparison. Compare annual accounts ↗
Recently founded means a recorded 2023–2026 founding year and no recorded parent, acquirer or public-company status. These companies are not labelled startups without that separate classification.
Explore classified startups in Radar ↗A few useful ratios bring the size of this ecosystem into perspective.
86 of 1,443 tracked companies have open roles.
233 of 1,443 tracked companies have a recorded round.
Share of disclosed capital received by the three largest recorded recipients.
Midpoint of 297 rounds with a disclosed amount.
Scale is concentrated. Opportunity is broader. The three largest funding recipients hold 31.0% of disclosed capital, while 83.9% of tracked companies have no recorded funding round.
Explore the segments →Recorded company formation and disclosed funding across the complete annual series shown.
Sum of recorded funding rounds · USD
| Year | Funding (USD) | Founded | Raising |
|---|---|---|---|
| 2016 | $49.57M | 98 | 14 |
| 2017 | $55.49M | 77 | 23 |
| 2018 | $41.78M | 91 | 22 |
| 2019 | $97.84M | 90 | 32 |
| 2020 | $123.43M | 96 | 29 |
| 2021 | $211.31M | 75 | 27 |
| 2022 | $101.36M | 40 | 32 |
| 2023 | $125.98M | 36 | 30 |
| 2024 | $178.1M | 14 | 21 |
| 2025 | $320.75M | 1 | 23 |
Share of all disclosed company funding.
394 recorded rounds since 2016
Recorded participation in healthtech company rounds since 2016.
Backed by EQT.
Backed by Insight Partners and Siemens Healthineers.
Backed by .
Backed by Intervest and McPike Global Family Office and others.
Backed by .
Backed by Capricorn Partners and BOM and others.
Backed by 819 Capital Partners and Thuja Capital and others.
Backed by Innovation Industries and Partners in Equity and others.
Backed by Partners in Equity and Health Innovations and others.
Backed by Intervest and McPike Global Family Office and others.
Backed by Innovation Industries and Invest-NL and others.
Participating investors were not recorded in this snapshot.
Backed by IFHA and ELMA Philanthropies and others.
Backed by Invest-NL and kineo finance and others.
Backed by Invest-NL and Olympic Investment and others.
Backed by Insight Partners and Siemens Healthineers and others.
Backed by Invest-NL and Europa and others.
No reviewed exact national-ID connector has yet been qualified for Netherlands; this is a checked implementation boundary, not evidence that filings are absent.
How the the Netherlands companies on this page show up online: the sites people visit, the apps they install, and how often those apps ship.
27 of the 1,443 companies on this page carry a measured traffic record (1.9%); these are the largest of those, by monthly visits. The median among them is 110,375 visits.
| Company | Monthly visits | Authority | Mobile |
|---|---|---|---|
| Shop Apothekeshop-apotheke.com | 10,569,958 | 74 | 79.2% |
| 24Baby24baby.nl | 1,895,670 | 64 | 90.5% |
| Farmalinefarmaline.be | 1,749,033 | 61 | 69% |
| Uw Zorg onlineuwzorgonline.nl | 1,134,456 | 40 | 70.8% |
| Positive Psychologypositivepsychology.com | 993,828 | 68 | 55% |
| Body&Fitbodyandfit.com | 672,768 | 46 | 71.5% |
| Dokteronlinedokteronline.com | 309,052 | 43 | 68.1% |
| Clinicmindsclinicminds.com | 222,088 | 29 | 78.1% |
| MyEigenPlanmijneigenplan.nl | 221,617 | 27 | 89.9% |
| ZorgDomeinzorgdomein.com | 149,781 | 40 | 73.4% |
Visits and authority are third-party web estimates, not company-reported figures.
205 of these companies (14.2%) publish at least one Android app — 304 apps in all, carrying 30.2M installs between them.
| App | Installs | Rating | Store category |
|---|---|---|---|
| Shop Apotheke: E-Rezept AppShop Apotheke | 8.4M | 4.6 | Medical |
| Weight Loss Tracker & BMI AppSelantoApps | 4.1M | 4.7 | Health & Fitness |
| Health SyncHealth Sync | 3.8M | 4.3 | Health & Fitness |
| SkinVision - Find Skin CancerSkinVision | 1.9M | 3.4 | Medical |
| WorrydollsWorrydolls | 1.2M | 4.8 | Health & Fitness |
| Uw Zorg OnlineUw Zorg online | 1.1M | 3.5 | Medical |
| BeterDichtbijBeterDichtbij | 1.1M | 4.6 | Medical |
| MijnZorgAppMijnZorgApp | 822.1K | — | Health & Fitness |
| AI Skin Scanner & Mole checkerSkinive | 578.3K | 4.1 | Medical |
| Do I Snore or GrindSleep.ai | 564.1K | 3.7 | Medical |
Installs are lifetime totals to date at the June 2026 store reading — a measure of reach, not of people using an app today.
The busiest app inside each of this page’s own segments, with the quarterly release trend behind it (2024Q1–2026Q2).
| Segment | Apps | Installs | Leading app | Release trend |
|---|---|---|---|---|
| Disease Self Management | 70 | 14.6M | Weight Loss Tracker & BMI App 4.1M | |
| Healthcare Booking Platforms | 36 | 12.2M | Shop Apotheke: E-Rezept App 8.4M | |
| Pet Tech | 3 | 8.4M | VETTS 4.5K | |
| Wearable Technology | 24 | 4.7M | My TANITA – Healthcare App 333K | |
| Healthcare It | 185 | 4.1M | MijnZorgApp 822.1K | |
| Fitness & Wellness Tech | 16 | 1.6M | Worrydolls 1.2M | |
| Online Health Information | 5 | 1.1M | BeterDichtbij 1.1M | |
| Artificial Intelligence | 5 | 626.8K | AI Skin Scanner & Mole checker 578.3K |
A company can carry several segment tags, so these rows overlap and should not be added together. Trend lines are zero-based and share one quarter grid, so a flat line is a quiet segment, not a missing one.
New apps published, beside apps whose most recent update landed in that quarter — the second bar is how much of the shelf is still being maintained.
Darker bars are new releases, lighter bars apps updated. 193 of 304 apps carry a release date. The series ends at 2026Q1, the last quarter that closed before the June 2026 reading.
Explore the segments behind the headline numbers.
Rank segments by scale, hiring or disclosed funding.
Companies can sit in several segments. Counts and funding overlap.
The largest measured segment in this report snapshot.
57 companies hiring · $1.15B disclosed funding
Explore in RadarCommon revenue models; a company can use more than one.
Recorded corporate activity linked to companies in this landscape.
ScreenPoint Medical raised $14M growth funding for breast imaging AI.
Nanomi has completed the full acquisition of VISUfarma B.V., Netherlands. Consequently, VISUfarma and its subsidiaries have become wholly owned subsidiaries of Nanomi effective April 1, 2026.
Funding for Startups ATRO Medical closed a €3 million (~USD $3.5 million) financing round.
NEW YORK — Automated phlebotomy firm Vitestro said Tuesday that it has raised $70 million in an oversubscribed Series B funding round.
In the Netherlands, QDI Systems obtained up to €7.5 million in investment and EIC support to advance quantum-dot-based X-ray and SWIR imaging technologies for medical and industrial applications.
Private equity investor Main Capital Partners has acquired a majority stake in IQ Messenger (IQM).
Now eight of the 12 businesses have each won £200,000 funding.
Investment firm Holland Capital, active in Healthcare and Technology in the Benelux and Germany, today announces the acquisition of its portfolio company HealthConnected to software company Visma.
Sleep.ai, a Carlsbad, CA-based healthtech company that provides AI-powered sleep solutions, has raised $5.5 million in venture funding.
Ireland-based CardiacBooster, together with partners FIRE1 and Integer Holdings, has been awarded €9.3 million from Ireland’s Disruptive Technologies Innovation Fund (DTIF) to accelerate the development of its novel mechanical cardiac support system.
Top 7 categories among 63 recorded events in the 24-month window.
4 tracked people moves
Appointment Chief Executive Officer
Appointment Chief Executive Officer
Appointment Chief Executive Officer
Appointment Chief Operating Officer and Managing Director
1 recorded customer wins
Customer: capri groupFashion
Company-linked deal reports; status is preserved as recorded.
| Acquirer → target | Status | Date | Value / context |
|---|---|---|---|
| Nanomi→Multicare Pharmaceuticals Philippines Inc. | Announced | 2026-04-02 | $39.6M |
| Nanomi→visufarma | Completed | 2026-04-01 | Not stated in snapshot |
| main capital partners→IQ Messenger ↗ | Announced | 2026-02-18 | Not stated in snapshot |
| visma→HealthConnected ↗ | Announced | 2025-09-17 | Not stated in snapshot |
| robidus→& niped ↗ | Announced | 2025-05-23 | Not stated in snapshot |
| NORD Holding Small Cap GmbH & Co. KG→Medxpert ↗ | Announced | 2025-03-05 | Not stated in snapshot |
A discussion or rumour is not a completed transaction. An unstated value is not zero.
3 postings in the preceding 12 months. The full 49-posting snapshot covers 41 employers.
2 tracked postings mention remote work.
26 postings specify a level.
Top skills across 49 tracked postings in the available jobs snapshot.
| Company | Employees |
|---|---|
| Malvern Panalytical ↗ | 1,771 |
| Van Raam ↗ | 245 |
| ExpertCollege ↗ | 211 |
| pinkroccade healthcare ↗ | 201 |
| witec ↗ | 130 |
| CarePay ↗ | 115 |
| dunlee, a division of philips ↗ | 101 |
| ScreenPoint ↗ | 58 |
638 founders and chief executives across 517 companies.
Chairman Marine Construction Technologies & Resolute Medical, JointMetrix Medical. UCLA MBA 2000
Ex-Cellnovo, Swanturbines. Swansea University 2007
Ex-Co-Founder & CEO Zarafa, Connectux, Arthur DLittle. Delft University of Technology MSc 1998
Ex - Chief Medical Officer Indigo, Abbott Vascular, Kyphon, KU Leuven 1996
Ex- M-TIBA, McKinsey & Company. INSEAD Master of Business Administration (M.B.A.) 2015…
Co-Founder-Perspectum · The University of Manchester MS 1967, The Australian National University PhD 1970
CEO, AkkoLens International bv
Ex- Pulsify Medical, Novuqare Hospital Equipment. Leiden University Masters, Theoretical Physics 1990, Rotterdam School of Management…
Founder Elana. University of Groningen BS 1989 & MSc 1995
Lavoisier, Ex -Van Paassen Consultancy, TNO Prevention and Health, Polymarin. Delft University of Technology 1981
University of Twente BSc 2011, MSc 2014
Nadeno Nanoscience, ex-Talent Accelerator Programme For Biobusiness, ex-Gouden Kiem, Private, 2015
63 profiles with education records.
5 profiles with prior-work records.
Profiles cover recorded founders and leaders; contact details remain in Radar.
29,171 articles in the measured 12-month window.
Healthtech coverage across Netherlands · articles per complete quarter
| Quarter | Articles |
|---|---|
| 2021Q2 | 5,397 |
| 2021Q3 | 4,929 |
| 2021Q4 | 5,020 |
| 2022Q1 | 5,265 |
| 2022Q2 | 5,780 |
| 2022Q3 | 4,930 |
| 2022Q4 | 5,834 |
| 2023Q1 | 5,535 |
| 2023Q2 | 6,377 |
| 2023Q3 | 5,557 |
| 2023Q4 | 5,836 |
| 2024Q1 | 6,329 |
| 2024Q2 | 6,742 |
| 2024Q3 | 6,886 |
| 2024Q4 | 6,270 |
| 2025Q1 | 12,203 |
| 2025Q2 | 6,556 |
| 2025Q3 | 5,978 |
| 2025Q4 | 8,278 |
| 2026Q1 | 8,001 |
Article volume measures coverage, not market sales.
76 recorded company events across 30 companies; percentages use that event total.
Healthtech coverage across Netherlands · ranked by full-period article count.
Recent and prior counts use the source comparison windows.
Healthtech coverage across Netherlands
| Keyword | Recent | Prior | Change |
|---|---|---|---|
| geopolitical alliances | 168 | 19 | 784% |
| multilateral diplomacy | 127 | 18 | 606% |
| stock performance | 117 | 45 | 160% |
| financial control software | 92 | 48 | 92% |
| diplomatic strategies | 77 | 21 | 267% |
| payroll management systems | 60 | 30 | 100% |
| financial reporting tools | 59 | 31 | 90% |
| payroll processing platforms | 59 | 31 | 90% |
| payroll processing software | 58 | 28 | 107% |
| investment deal | 52 | 10 | 420% |
| intuitive painting | 5 | 153 | -97% |
| non-representational art | 7 | 123 | -94% |
| international courts | 56 | 102 | -45% |
| gender critique art | 2 | 101 | -98% |
| action painting | 3 | 87 | -97% |
Healthtech coverage across Netherlands
garage rock resurgence, fuzz guitar revival, back-to-basics rock
38.2% critical · 42.0% positiveconceptual rock albums, avant-garde rock, complex rock narratives
33.5% critical · 57.2% positivequarterly results, quarterly financials, earnings report
28.5% critical · 59.3% positiveHealthtech coverage across Netherlands. Topic labels describe recorded classifications and can include broad context.
53,214 papers in the recorded worldwide scope.
Tone counts: 46,301 positive · 2,052 neutral · 4,861 negative.
Landmark: Implementation strategies: recommendations for specifying and reporting
Landmark: Deep Learning for Health Informatics
Landmark: Fostering implementation of health services research findings into practice: a consolidated framework for advancing implementation science
Common problems researchers identify · 0119.0% of this theme group
Researchers examine factors and methods that affect the ability of health systems to remain functional under stress.
Health informatics (400) · Health administration (281) · Nursing research (250) · Public health (273)
Resilient Health Care: a systematic review of conceptualisations, study methods and factors that develop resilience
Health systems resilience in practice: a scoping review to identify strategies for building resilience
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Common problems researchers identify · 0218.9% of this theme group
Papers discuss obstacles in discovering and repurposing drugs for multifaceted diseases and oncology.
Drug discovery (321) · Drug (197) · Drug development (103) · Disease (155)
A perspective on multi‐target drug discovery and design for complex diseases
Drug repurposing in oncology: Compounds, pathways, phenotypes and computational approaches for colorectal cancer
| Year | Share index |
|---|---|
| 2022 | 157.3 |
| 2023 | 161.8 |
| 2024 | 169.7 |
| 2025 | 211.5 |
Common problems researchers identify · 0315.9% of this theme group
Studies highlight difficulties in adopting eHealth tools and digital transformation across diverse health care settings.
Digital health (627) · Health care (357) · Digital transformation (69) · eHealth (97)
Technology and Universal Health Coverage: Examining the role of digital health
Engagement With and Acceptability of Digital Media Platforms for Use in Improving Health Behaviors Among Vulnerable Families: Systematic Rev
| Year | Share index |
|---|---|
| 2022 | 538.7 |
| 2023 | 553.0 |
| 2024 | 540.4 |
| 2025 | 843.9 |
Common problems researchers identify · 0414.7% of this theme group
Works focus on the practical challenges and assessment methods for remote clinical services.
Telemedicine (604) · Telehealth (394) · Health care (334) · Telerehabilitation (53)
Opportunities and challenges for telehealth within, and beyond, a pandemic
Strategies for Evaluating Telehealth
| Year | Share index |
|---|---|
| 2022 | 542.2 |
| 2023 | 554.7 |
| 2024 | 541.1 |
| 2025 | 844.0 |
Common problems researchers identify · 0511.7% of this theme group
Research points to gaps in molecular diagnostics, biomarker validation, and resistance management for personalized cancer care.
Precision medicine (480) · Personalized medicine (238) · Disease (116) · Precision oncology (28)
Personalized Cancer Medicine: Molecular Diagnostics, Predictive biomarkers, and Drug Resistance
Personalizing Oncology: Perspectives and Prospects
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Common problems researchers identify · 0610.9% of this theme group
Articles address safety concerns, energy sourcing, and evolving regulatory frameworks for moderate‑risk devices.
Medical device (221) · Wearable computer (50) · Medical equipment (27) · Risk analysis (34)
Energy sources and their development for application in medical devices
Medical Devices and Health — Creating a New Regulatory Framework for Moderate-Risk Devices
| Year | Share index |
|---|---|
| 2022 | 40.4 |
| 2023 | 42.2 |
| 2024 | 43.7 |
| 2025 | 72.1 |
Common problems researchers identify · 078.8% of this theme group
Analyses quantify COVID‑19’s impact on remote care usage and the specific challenges it created.
Pandemic (394) · Coronavirus disease 2019 (274) · 2019-20 coronavirus outbreak (69) · Telemedicine (258)
Quantifying the Impact of COVID-19 on Telemedicine Utilization: Retrospective Observational Study
Telemedicine Evaluations in Neuro-Ophthalmology During the COVID-19 Pandemic: Patient and Physician Surveys
| Year | Share index |
|---|---|
| 2022 | 655.3 |
| 2023 | 440.6 |
| 2024 | 327.7 |
| 2025 | 212.1 |
Cautions · 0119.8% of this theme group
Authors urge careful evaluation of effectiveness and patient satisfaction before broad telehealth deployment.
Telemedicine (762) · Telehealth (476) · Telerehabilitation (118) · Health care (319)
The Role of Telemedicine in Improving Healthcare Outcome: A Review
Assessing the Efficiency and Patient Satisfaction of Telemedicine in Managing Chronic Health Conditions
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Cautions · 0219.8% of this theme group
Studies caution about technical, logistical, and quality‑assessment hurdles when implementing digital tools in underserved areas.
Health informatics (239) · Health administration (157) · Nursing research (113) · Medical device (92)
Challenges of using e-health technologies to support clinical care in rural Africa: a longitudinal mixed methods study exploring primary hea
Development and analysis of quality assessment tools for different types of patient information – websites, decision aids, question prompt l
| Year | Share index |
|---|---|
| 2022 | 23.2 |
| 2023 | 21.1 |
| 2024 | 27.6 |
| 2025 | 44.8 |
Cautions · 0315.3% of this theme group
Papers highlight regulatory and predictive challenges surrounding biomarkers and personalized pharmacokinetic modeling.
Drug discovery (202) · Drug (160) · Pharmacogenomics (109) · Pharmacogenetics (64)
Biomarkers: Opportunities and Challenges for Drug Development in the Current Regulatory Landscape
Can We Predict Clinical Pharmacokinetics of Highly Lipophilic Compounds by Integration of Machine Learning or In Vitro Data into Physiologic
| Year | Share index |
|---|---|
| 2022 | 154.6 |
| 2023 | 158.9 |
| 2024 | 165.9 |
| 2025 | 206.7 |
Cautions · 0414.7% of this theme group
Research points to mixed efficacy, adoption barriers, and user‑experience concerns for online psychological therapies.
Digital health (480) · Psychological intervention (265) · Mental health (159) · Health care (262)
Digital Health Interventions to Enhance Prevention in Primary Care: Scoping Review
Digital Health Interventions for Promoting Healthy Aging: A Systematic Review of Adoption Patterns, Efficacy, and User Experience
| Year | Share index |
|---|---|
| 2022 | 790.2 |
| 2023 | 807.5 |
| 2024 | 810.9 |
| 2025 | 1159.7 |
Cautions · 0511.2% of this theme group
Analyses reveal clinician hesitancy and workflow disruptions when shifting to remote care during the pandemic.
Pandemic (431) · Coronavirus disease 2019 (360) · Telemedicine (348) · 2019-20 coronavirus outbreak (77)
Community Mental Health Clinicians’ Perspectives on Telehealth During the COVID-19 Pandemic: Mixed Methods Study
Exploring Ophthalmologists’ Adoption of Telemedicine during the COVID-19 Pandemic: A Mixed Methods Study
| Year | Share index |
|---|---|
| 2022 | 544.1 |
| 2023 | 376.7 |
| 2024 | 243.3 |
| 2025 | 191.2 |
Cautions · 0610.3% of this theme group
Works discuss gaps in awareness, data interpretation, and practical uptake of personalized oncology approaches.
Precision medicine (249) · Personalized medicine (164) · Cancer (103) · Oncology (57)
Awareness, Understanding, and Adoption of Precision Medicine to Deliver Personalized Treatment for Patients With Cancer: A Multinational Sur
Role of Proteins in Oncology: Advances in Cancer Diagnosis, Prognosis, and Targeted Therapy—A Narrative Review
| Year | Share index |
|---|---|
| 2022 | 767.8 |
| 2023 | 1043.6 |
| 2024 | 798.0 |
| 2025 | 771.4 |
Cautions · 078.8% of this theme group
Authors stress the need for transparent, accountable AI systems to avoid bias and maintain patient safety.
Applications of artificial intelligence (102) · Transformative learning (77) · Health care (188) · Precision medicine (102)
Artificial intelligence in healthcare: revolutionizing precision medicine, predictive analytics, and ethical considerations in autonomous di
Artificial Intelligence in Medicine: Transforming Diagnosis, Treatment, and Healthcare Delivery
| Year | Share index |
|---|---|
| 2022 | 534.7 |
| 2023 | 549.6 |
| 2024 | 538.1 |
| 2025 | 839.2 |
Opportunities · 0118.0% of this theme group
Research explores models and design strategies that improve user interaction with health informatics tools.
Digital health (282) · Health care (348) · Health informatics (142) · Psychological intervention (156)
Development of an Evidence-Based Conceptual Model of the Health Care Sector Under Digital Transformation: Integrative Review
HCI-modelling for improving the clinical usability of digital health technologies
| Year | Share index |
|---|---|
| 2022 | 541.3 |
| 2023 | 554.6 |
| 2024 | 543.2 |
| 2025 | 853.3 |
Opportunities · 0216.5% of this theme group
Papers showcase computational screening and docking methods accelerating discovery of novel therapeutic candidates.
Drug discovery (281) · In silico (99) · Drug (155) · Docking (85)
Exploring Cimetidine\nas a Potential Therapeutic Attenuator\nagainst Amyloid Formation in Parkinson’s Disease: Spectroscopic\nand Microscopi
Design, Synthesis,\nand Biological Evaluation of 5‑Formyl-pyrrolo[3,2‑<i>b</i>]pyridine-3-carboxamides as New Selective, Potent,
| Year | Share index |
|---|---|
| 2022 | 167.5 |
| 2023 | 172.4 |
| 2024 | 180.4 |
| 2025 | 218.9 |
Opportunities · 0313.8% of this theme group
Studies highlight how molecular docking and virtual screening expand chemical space exploration for new medicines.
Drug discovery (536) · Computational biology (222) · Drug (224) · Chemical space (66)
Assessing molecular docking tools: understanding drug discovery and design
Molecular Docking in Computer-Aided Drug Discovery: A Powerful Tool for Targeted Therapeutics
| Year | Share index |
|---|---|
| 2022 | 281.3 |
| 2023 | 298.1 |
| 2024 | 330.7 |
| 2025 | 367.6 |
Opportunities · 0413.7% of this theme group
Works identify promising remote therapy models for seniors and palliative care communication.
Telemedicine (475) · Telehealth (353) · Telerehabilitation (87) · Physical therapy (75)
Urgent and non-emergent telehealth care for seniors: Findings from a multi-site impact study
Telehealth for the study of palliative care communication: opportunities, methodological challenges, and recommendations
| Year | Share index |
|---|---|
| 2022 | 51.7 |
| 2023 | 48.4 |
| 2024 | 44.2 |
| 2025 | 63.5 |
Opportunities · 0512.7% of this theme group
Research emphasizes leveraging pharmacogenomics and deep learning to tailor treatments for complex diseases.
Precision medicine (283) · Personalized medicine (216) · Disease (142) · Pharmacogenomics (61)
Pathways to personalized medicine—Embracing heterogeneity for progress in clinical therapeutics research in Alzheimer's disease
Deep Learning for Precision Medicine: Advancing Personalized Treatment Plans in Oncology
| Year | Share index |
|---|---|
| 2022 | 1255.2 |
| 2023 | 1115.6 |
| 2024 | 1012.0 |
| 2025 | 1296.9 |
Opportunities · 0612.7% of this theme group
Articles describe how connected devices support remote patient tracking and health management in diverse populations.
Wearable computer (117) · Medical device (84) · Remote patient monitoring (76) · Internet of Things (49)
Wearable technology. Health-care solutions for a growing global population.
IoT Based Effective Wearable Healthcare Monitoring System For Remote Areas
| Year | Share index |
|---|---|
| 2022 | 40.5 |
| 2023 | 42.2 |
| 2024 | 44.3 |
| 2025 | 74.3 |
Opportunities · 0712.5% of this theme group
Studies focus on circulating tumor cell analysis and molecular markers to refine individualized cancer treatment.
Cancer (241) · Precision medicine (207) · Breast cancer (90) · Lung cancer (44)
Bioinformatics-Based Analysis of Circulating Tumor Cells: A Methodological Overview of Personalized Cancer Treatment
[Molecular biomarkers in breast cancer : advances in precision medicine].
| Year | Share index |
|---|---|
| 2022 | 776.6 |
| 2023 | 1055.1 |
| 2024 | 810.2 |
| 2025 | 787.3 |
Orientation shares compared with 25,000 papers in the reference sample.
| Research orientation | This field | Reference sample |
|---|---|---|
| Promising | 29.7% | 37.4% |
| Problem-identifying | 29.0% | 9.9% |
| Descriptive | 18.8% | 17.6% |
| Breakthrough | 12.7% | 25.9% |
| Cautionary | 6.4% | 4.4% |
| Comparative | 2.5% | 3.9% |
| Critical | 0.9% | 0.9% |
Counts and shares refer to the stated research pool. A low count describes how much of that research is recorded here, not the absence of a real-world concern.
| Concern / example paper | Papers | Share | Raised as a problem | Worldwide share |
|---|---|---|---|---|
| Privacy & surveillanceThe future of digital health with federated learning | 4,573 | 2.66% | 2,251 (49.2%) | 2.66% |
| Safety & misuseImpact of Rumors and Misinformation on COVID-19 in Social Media | 292 | 0.17% | 167 (57.2%) | 0.17% |
| Bias & fairnessChallenges and recommendations for wearable devices in digital health: Data quality, interoperability, health equity, fa | 99 | 0.06% | 45 (45.5%) | 0.06% |
| Hardware, e-waste & supply chainE-waste for health: recycling smartphones for health monitoring | 24 | 0.01% | 7 (29.2%) | 0.01% |
| Concentration of compute powerDemonopolizing Medical Knowledge | 16 | 0.01% | 7 (43.8%) | 0.01% |
| Labour & data workNew Work—New Interventions: Digital Occupational Health Interventions and the Co-Creation of a Human-Centered Future of | 11 | 0.01% | 6 (54.5%) | 0.01% |
| Energy & datacenter footprintSUSTAINABLE GREEN COMPUTING FOR MEDICAL APPLICATIONS: ADVANCING RESPONSIBLE HEALTHCARE IT | 10 | 0.01% | 4 (40.0%) | 0.01% |
| Carbon & emissions of computeSustainable AI-Enabled UAV Healthcare Logistics: Environmental, Social, and Governance Implications from a PRISMA-ScR Re | 3 | 0.0% | 1 (33.3%) | 0.0% |
| Water use | 0 | 0.0% | 0 (%) | 0.0% |
Institution and researcher rankings use citations to their covered work. Research scope: worldwide. This may be broader than the company geography.
Published patent filings in the recorded source window.
Company counts, hiring and disclosed funding across the recorded hubs.
38.3% across the displayed hubs
15 companies hiring · $228.6M disclosed funding
Explore companies in Amsterdam ↗
12.8% across the displayed hubs
4 companies hiring · $344.5M disclosed funding
Explore companies in Utrecht ↗
11.8% across the displayed hubs
5 companies hiring · $453.0M disclosed funding
Explore companies in Eindhoven ↗
9.9% across the displayed hubs
7 companies hiring · $83.5M disclosed funding
Explore companies in Rotterdam ↗
7.9% across the displayed hubs
4 companies hiring · $122.2M disclosed funding
Explore companies in Nijmegen ↗
7.4% across the displayed hubs
3 companies hiring · $26.4M disclosed funding
Explore companies in Leiden ↗
6.6% across the displayed hubs
2 companies hiring · $38.5M disclosed funding
Explore companies in Maastricht ↗5.3% across the displayed hubs
2 companies hiring · $15.9M disclosed funding
Explore companies in The Hague ↗Clear definitions for making better comparisons.
It measures the tracked company ecosystem, recorded funding, hiring and other available evidence. It is not a market-size estimate.
No. A company can belong to several segments, so segment counts and funding can overlap.
A dash or unavailable panel means the current reviewed source snapshot does not support that figure.
Company ecosystem snapshot: 31 August 2026. Funding is recorded in USD; filed accounts retain their stated currency and reporting basis. Each section identifies its own coverage. The news and research behind these sections is explorable in Prism.
Canonical landscape ↗